A general and fast method to generate multiple site directed mutations.
Explore the source record for details and available documents.
Herpesvirus 4, Human↗
Biomedical subjects
A Sergeant
Publications and source records attributed to A Sergeant.
Role of activator protein-1 and methylation function in 12-O-tetradecanoylphorbol-13-acetate--mediated inhibition of differentiation of Friend erythroleukemia cells.
Friend erythroleukemia cells (FELCs) differentiate after hexamethylene-bis-acetamide treatment. This differentiation is characterized by an increase in beta-globin gene expression that is followed by appearance of the hemoglobin. Phorbol-ester tumor promoters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA), inhibit differentiation of TPA-sensitive cells but not TPA-resistant cells. We have shown that the increase in beta-globin expression is inhibited by TPA in a TPA-sensitive clone but not in a TPA-resistant clone. To study the molecular mechanisms of regulation of gene expression by TPA, we examined the possible involvement of gene methylation and the TPA-responsive element (TRE). Both clones showed similar patterns of methylation around the beta-globin gene. Moreover, TPA-induced TRE binding and TRE enhancer activity were similar in both variants. These results suggest that the TPA inhibition of induced differentiation may not be explained by regulation of the methylation state. The activator protein-1 also does not play a crucial role in the sensitivity of FELCs to TPA.
Animals↗
Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter.
In cells latently infected with Epstein-Barr virus, the switch from latency to productive infection is linked to the expression of two Epstein-Barr virus transcription factors called EB1 and R. R is an enhancer factor, and an R-responsive element (RRE) has been identified in the BMLF1 promoter. In this study, we have used bidirectional deletion mutagenesis to delineate the BMLF1 RRE (RRE-M) to a 44-bp sequence. We also show that R expressed from a recombinant vaccinia virus protects RRE-M against digestion by DNase I. Using mobility shift assays and dimethyl sulfate interferences, we have characterized the contact points between in vitro-translated R and the DNA. R binds in vitro to one site by simultaneously contacting two sequences within the site, which are separated by 8 bp: 5'-catGTCCCtctatcatGGCGCagac-3'. Site-directed mutagenesis of this sequence completely impaired the binding of R in vitro and rendered the BMLF1 promoter nonresponsive to R. The results suggest that the R-inducible BMLF1 enhancer is composed of a single R-binding site, called RRE-M.
Binding Sites↗
The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.
Regulation of replicative functions in the Epstein-Barr virus (EBV) genome is mediated through activation of a virally encoded transcription factor, Z (BZLF1). We have shown that the Z gene product, which binds to AP-1 sites as a homodimer and has sequence similarity to c-Fos, can efficiently activate the EBV early promoter, BMRF1, in certain cell types (i.e., HeLa cells) but not others (i.e., Jurkat cells). Here we demonstrate that the c-myb proto-oncogene product, which is itself a DNA-binding protein and transcriptional transactivator, can interact synergistically with Z in activating the BMRF1 promoter in Jurkat cells (a T-cell line) or Raji cells (an EBV-positive B-cell), whereas the c-myb gene product by itself has little effect. The simian virus 40 early promoter is also synergistically activated by the Z/c-myb combination. Synergistic transactivation of the BMRF1 promoter by the Z/c-myb combination appears to involve direct binding by the Z protein but not the c-myb protein. A 30-bp sequence in the BMRF1 promoter which contains a Z binding site (a consensus AP-1 site) is sufficient to transfer high-level lymphoid-specific responsiveness to the Z/c-myb combination to a heterologous promoter. That the c-myb oncogene product can interact synergistically with an EBV-encoded member of the leucine zipper protein family suggests c-myb is likely to engage in similar interactions with cellularly encoded transcription factors.
Amino Acid Sequence↗
Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation.
In cells latently infected with EBV, the switch from latency to a productive infection is linked to the expression of two transcriptional activators, the upstream element factor EB1 and the enhancer factor R. R activates by interacting directly with specific DNA sequences called RREs (R Responsive Elements). Each binding site covers about 18 bp, where R simultaneously contacts two core sequences separated by 5 to 7 bp (1). Here we show that R binds in vitro as a homodimer to an RRE, and that stable homodimers can also form in solution in the absence of DNA. By functional analysis of deletion and insertion mutants of R, we have localized the DNA binding region within the 280 N-terminal amino acids and the dimerization region within the 232 N-terminal amino acids. As no obvious homologies were detected with other known DNA binding or dimerization motifs, R could contain novel protein structures mediating these functions. The transcriptional activation domain has been located in the C-terminal half of the protein. This domain contains two regions with structures already identified in other transcription factors: one region is rich in proline, the other rich in acidic residues.
Base Sequence↗
Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required.
The switch from latency to a productive infection in EBV-infected B cells is linked to the expression of two viral sequence-specific DNA-binding transcription factors called EB1 and R. EB1 shares sequence homologies with the bZIP family of proteins in the basic region required for specific DNA interaction. Here, we provide evidence that EB1 and R can synergistically activate specific transcription, and that overexpressed, unbound EB1, represses the R-induced transcription ('squelching'). In order to identify the EB1 domains involved in transcriptional activation, transcriptional synergy and transcriptional repression, we performed extensive mutagenesis of the EB1 protein. Results show that five segments (region 1 to region 5), localized at the N-terminus of EB1 exhibit characteristics of activating domains, since they are required for full transcriptional activity, without obvious role in DNA-binding, or the nuclear localization. Two domains rich in basic amino-acids are required for the nuclear localization of EB1. One domain is within the basic region B, also necessary for specific and stable interaction between EB1 and its cognate DNA sequences. It is also shown that the 'activation' domain, and more surprisingly the DNA-binding domain of EB1, may interact with a factor(s), essential for R-induced activation, and probably required for synergy between EB1 and R.
Amino Acid Sequence↗
Evidence for a functional glucocorticoid responsive element in the Epstein-Barr virus genome.
Glucocorticoids induce the expression of Epstein-Barr virus early antigens in latently infected Daudi cells. By sequence analysis, we found that fragment C of the BamHI digested Epstein-Barr virus B95-8 genome contains a region with a large degree of homology to the glucocorticoid responsive element of known glucocorticoid-regulated genes. By transfection experiments in Daudi and HeLa cells, different lengths of this region, cloned in front of the bacterial chloramphenicol acetyl transferase linked to the Herpes Simplex virus thymidine kinase promoter (pBLCAT.2), were assayed for their responsiveness to dexamethasone; our results led us to the conclusion that the hormonal effect observed was mediated by a minimal sequence of 15 base pairs presenting 85% homology with the consensus glucocorticoid responsive element sequence.
Base Sequence↗
[Regulation of Epstein-Barr virus early gene expression].
Explore the source record for details and available documents.
Gene Expression Regulation, Viral↗
The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein.
In cells latently infected with EBV, the switch from latency to productive infection is linked to the expression of two EBV transcription factors called EB1 (or Z) and R. EB1 is an upstream element factor which has partial homology to the AP1/ATF family, whereas R is an enhancer factor. In the R-responsive enhancer of the replication origin only active during the EBV lytic cycle (ORIIyt), R-responsive elements are located in a region of about 70 bp (RRE-DR). Here we show that R, produced either by in vitro translation, or present in nuclear extracts from HeLa cells constitutively producing R, binds directly to and protects against DNAase I digestion, two regions in RRE-DR. Using mobility shift assay and DMS interference, we have characterized the contact-points between R and the DNA. Two binding sites, RRE-DR1 and RRE-DR2, were characterized and are contiguous in RRE-DR. R binds to these two sites probably by simultaneously contacting two sequences within the sites, which are separated by 7 bp in RRE-DR1, cctGTGCCttgtcccGTGGACaatgtccc, and by 6bp in RRE-DR2, caatGTCCCtccagcGTGGTGgctg. Direct interaction of R with its cognate sequences is conferred by its N-terminal 355 amino-acids. Directed mutagenesis in RRE-DR, of either R-binding site, impaired binding of R in vitro and, as assayed by transient expression in HeLa cells, impaired R-activation by a factor of two. This suggests that RRE-DR1 and RRE-DR2 do not respond cooperatively to R.
Base Sequence↗
Tax1 induction of the HTLV-I 21 bp enhancer requires cooperation between two cellular DNA-binding proteins.
Activation of the HTLV-I promoter by the viral Tax1 transactivator is mediated by a 21 bp sequence motif imperfectly repeated three times and composed of three exactly conserved domains (A, B and C from 5' to 3'). We show here that the Tax1 response requires the integrity of the B domain and of at least one of the flanking A or C domains. We have identified three cellular proteins which bind specifically to the 21 bp motif. One of these is the already well-characterized transcription factor ATF. The other two, namely HEB1 and HEB2, are specific for the 21 bp motif. HEB1 can bind to either domain A or C, but binding of ATF and HEB2 is determined by domain B. However, neither domain B alone, nor ATF/CREB binding sites respond significantly to Tax1. We therefore propose that Tax1 induction of the 21 bp enhancer element requires interaction with the two different cellular proteins identified in this study: HEB1 and HEB2, rather than binding of the ATF factor.
Base Sequence↗
The Epstein-Barr virus (EBV) ORI1yt enhancer is not B-cell specific and does not respond synergistically to the EBV transcription factors R and Z.
The Epstein-Barr virus DR promoter is located upstream of the PstI repeats, and in addition to the TATA box, it contains an upstream region (positions -69 to -220) responsive to EB1 (Z) (the BZLF1-encoded transcription factor) and an enhancer with two functionally distinct domains, A and B. Domain B has been described as a B-cell-specific EB1-responsive element (P. M. Lieberman, J. M. Hardwick, and S. D. Hayward, J. Virol. 63:3040-3050, 1989) activated synergistically by EB1 and R, an EBV early product encoded by the open reading frame BRLF1 (M. A. Cox, J. Leahy, and J. M. Hardwick, J. Virol. 64:313-321, 1990). We show here that domain B is an R-responsive element in HeLa cells and is therefore not an EB1-responsive B-cell-specific element. However, there is an EB1-binding site (ZRE-B) located within the R-responsive enhancer region. ZRE-B can be deleted without affecting the R-dependent enhancer activity. Moreover, there is no cooperation or synergy between R and EB1 when activating the B domain (ZRE-B plus the R-responsive element) positioned as an enhancer. ZRE-B is therefore not part of the R-inducible enhancer. We have tested several subregions of the DR enhancer B domain, either alone or in combination, for their capacity to transmit the R-activating signal to the rabbit beta-globin promoter. We found that the R-responsive element is composed of four protoenhancers that span the whole B domain. These protoenhancers alone are weakly or not responsive to R. One of the protoenhancers contains the overlapping palindromes 5'-TTGTCCcgtGGACAAaTGTCC-3'. However, one palindrome, either alone or duplicated, or the overlapping palindromes did not respond to R.
B-Lymphocytes↗
The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites.
When expressed in Epstein-Barr virus (EBV) latently infected B cells, the EBV early protein EB1 trans-activates as many EBV early genes as does TPA. Several EB1 responsive elements (ZRE) have been identified in EBV early promoters and are located at relatively short distances from the TATA box. One of them (ZRE-M) overlaps with a consensus TPA responsive element (TRE) defined as an AP-1/c-jun/c-fos binding site and is located in an EBV promoter controlling the expression of the post-transcriptional activator EB2. Another (ZREZ) is located in the promoter controlling the expression of EB1 and does not respond to TPA. These two ZREs have no apparent sequence homology. Although EB1 activates transcription from the AP-1 enhancer sequence and from the ZREZ, the activation is severely impaired by distance, suggesting that EB1 is more likely to be a promoter factor than an enhancer factor. These properties also suggest that EB1 is not functionally related to c-jun and c-fos. However, since EB1 can activate transcription from AP-1 binding sites when properly positioned, the role of this factor in the oncogenic properties of EBV should be considered.
Base Sequence↗
Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators.
The Epstein-Barr virus (EBV) genome codes for several transcriptional trans-activators. One of them, the BZLF1 open reading frame (ORF)-encoded product EB1, is able to induce the productive cycle in infected B cells. From the cloning and characterization of full-length cDNAs, we found that EB1 could be made from three overlapping messenger RNAs expressed under the control of two different promoters that we call P1 and P2. The first mRNA, 1 kb long, is made from the P1 promoter and codes for EB1 alone. The two other mRNAs, respectively 3 and 4 kb long and made by facultative splicing, are bicistronic mRNAs. They code not only for the trans-activator EB1 but also for a second EBV transcriptional trans-activator R, encoded by the BRLF1 ORF. In effect, authentic EB1 and R proteins are expressed from the 3 and 4 kb long cDNAs as demonstrated by identification of the proteins with specific antisera. In addition, EB1 and R expressed from the 3 and 4 kb cDNAs activate transcription from their specific targets in the EBV early promoter DR.
Cell Line, Transformed↗
The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.
From the cloning and characterization of cDNAs, we found that the Epstein-Barr virus (EBV) open reading frame (ORF) BMLF1-BSLF2 coding for the early protein EB2 is present in several mRNAs generated by alternative splicing and expressed in the leftward direction from two promoters PM and PM1. The PM promoter controls the expression of two abundant mRNA species of 1.9 and 2 kilobases (kb), whereas the PM1 promoter controls the expression of at least three mRNAs 3.6, 4.0, and 4.4 kb long. The PM promoter probably overlaps with the PS promoter which controls the transcription of a 3.6-kb mRNA expressed in the rightward direction and containing the ORF BSRF1. Although it increases the amount of chloramphenicol acetyltransferase enzyme expressed from the chimeric pMCAT gene, EB2 is not a promiscuous trans-activator of gene expression and does not positively regulate its own expression from promoter PM. The EB2 activation is not promoter dependent but could possibly act by stabilizing mRNAs and increasing their translation. The PM promoter is, however, activated by the two EBV transcription trans-acting factors, EB1 and R, encoded by the EBV ORFs BZLF1 and BRLF1, respectively. EB1 activates the PM promoter from a consensus AP-1 binding site, and R activates the PM promoter from an enhancer.
Base Sequence↗
The Epstein-Barr virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities.
The Epstein-Barr Virus (EBV) DR promoter controlled the expression of the PstI repeat region IR4. This promoter was activated by the EBV trans-acting factor EB1, mainly at the transcriptional level, and the activation was mediated by the TATA box and two cis-acting regulatory regions, one proximal to the TATA box and one distal to the TATA box. The distal region had enhancer properties. In HeLa cells, it activated transcription from the herpes simplex virus type 1 thymidine kinase promoter linked to the chloramphenicol acetyltransferase gene when located in inverted orientation upstream of the thymidine kinase promoter or downstream of the chloramphenicol acetyltransferase gene coding sequence. This enhancer also activated transcription from the simian virus 40 early upstream regulatory elements. These results indicate that the DR These results indicate that the DR enhancer can constitutively activate heterologous promoters in HeLa cells. However, the DR enhancer was not active in EBV genome-negative B cell lines, but it became active when these cells were infected by EBV and when the expression of the EBV early genes was induced by EB1. This suggests that an EBV early gene product induces the DR enhancer activity. The DR promoter TATA box-proximal cis-acting regulatory element contained EB1-responsive sequences.
Enhancer Elements, Genetic↗
The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R.
The Epstein-Barr virus (EBV) DR promoter is located upstream of the PstI repeats, and besides the TATA box, it contains two cis-acting regulatory elements. One of them has enhancer properties. To define more precisely the functional region(s) in the DR enhancer, we generated 5' and 3' deletion mutants. These deletion mutants, which were transfected into various recipient cells of different origins, allowed us to identify two functionally distinct domains, A and B. Domain A was constitutively active in all cell lines tested, except in lymphoid B cells. Domain B was active in lymphoid B cells, and its activity required both EB1 (the BZLF1-encoded EBV trans-acting factor) and the presence of the EBV genome. This suggested that an EBV-encoded, EB1-inducible factor was activating the enhancer B domain. In effect, the B domain was trans-activated by R, an EBV early product encoded by the open reading frame BRLF1, and the activation by R occurred in epithelial, fibroblastic, and lymphoid cells. The R-responsive element has been reduced to 28 base pairs containing the double palindromic sequence TTGTCCCGTGGACAATGTCC. Both domains A and B act by increasing the initiation of specific RNAs.
Animals↗
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.
We have identified two Epstein--Barr virus (EBV) transacting factors which are involved in the transcriptional activation of EBV early promoters in latently infected Raji cells. In Raji cells, expression of the factor EB1 encoded by the open reading frame (ORF) BZLF1 is necessary and sufficient to disrupt latency. However, factor EB2 encoded by the ORF BMLF1- BSLF2 does not disrupt latency when expressed alone in Raji cells. Expression of an EBV activatable early promoter depends on the presence of both EB1 and EB2.
Cell Line↗
The SV40 enhancer influences viral late transcription in vitro and in vivo but not on replicating templates.
We have examined transcription from the SV40 late promoter in vitro and in vivo. In HeLa whole cell extracts, late transcription is efficient in the absence of T antigen but is impaired by enhancer specific point mutations. In vivo, when replication is prevented, transcription from the late promoter requires T antigen as well as a functional enhancer. However, enhancer sequences fail to potentiate late transcription from replicating templates although, under such conditions, enhancer binding factors do not become limiting. It appears that the SV40 late transcription unit is refractory to enhancer-mediated activation when it is located on a replicating template.
Antigens, Polyomavirus Transforming↗